Search

Discover the role of the work environment in the life and career of an employee with cancer.

… Wednesday, February 8, 2017 Summary Breast cancer patients who worked for supportive employers were more likely to hang onto their jobs after treatment than women who didn’t, according to a new study led by Memorial Sloan Kettering medical oncologist Victoria Blinder . Hear how one woman navigated life

Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor, according to a new study published today in The New England Journal of Medicine.

… Wednesday, June 18, 2025 Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor,

MSK has developed an arsenal of tests that are at the front lines of precision treatments. They target the structure of proteins that cause cancer, offering people new hope.

… Saturday, July 1, 2023 It was a major milestone a decade in the making. Inside a bustling lab at Memorial Sloan Kettering Cancer Center (MSK) on an otherwise ordinary Thursday in February 2023, specially trained technicians performed a unique test for the 100,000th time. The test was to analyze DNA from

A new study from researchers at MSK and Weill Cornell Medicine provides fresh insights about how cancers evolve when they metastasize — insights that could aid in developing strategies to improve the effectiveness of treatment.

… Monday, June 2, 2025 When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic complexity. A new study from researchers at Memorial Sloan Kettering Cancer Center (MSK) and Weill Cornell Medicine provides fresh insights about how cancers

Scott W. Lowe has joined Memorial Sloan Kettering Cancer Center as a member of the Cancer Biology and Genetics Program in the Sloan Kettering Institute and Chair of the Geoffrey Beene Cancer Research Center.

… Saturday, October 1, 2011 Summary Scott W. Lowe has joined Memorial Sloan Kettering Cancer Center as a member of the Cancer Biology and Genetics Program in the Sloan Kettering Institute and Chair of the Geoffrey Beene Cancer Research Center. Scott W. Lowe has joined Memorial Sloan Kettering Cancer Center

A new therapy tested in mouse models appears to harness neutrophils, a type of white blood cell, to effectively prevent the spread of breast cancer cells.

… Thursday, December 1, 2011 Summary A new therapy tested in mouse models appears to harness neutrophils, a type of white blood cell, to effectively prevent the spread of breast cancer cells. A multidisciplinary team from Memorial Sloan Kettering Cancer Center has published research suggesting a potential

The broad-spectrum antibiotic piperacillin-tazobactam used as perioperative prophylaxis significantly reduced surgical site infection (SSI) in patients undergoing open pancreatoduodenectomy (PD, or the Whipple procedure) compared with the standard-of-care cefoxitin, according to results from the first-ever registry-linked surgical clinical trial conducted in North America. The findings, published in JAMA on April 20, support using piperacillin-tazobactam as a standard of care for this patient population.

… Thursday, April 20, 2023 The broad-spectrum antibiotic piperacillin-tazobactam used as perioperative prophylaxis significantly reduced surgical site infection (SSI) in patients undergoing open pancreatoduodenectomy (PD, or the Whipple procedure) compared with the standard-of-care cefoxitin, according

Dr. Brown, whose research has been shedding light on the development of the early life immune system and its relationship to autoimmunity, allergy, inflammation and cancer, was among 30 early career scientists nationwide selected for the 2025 class of scholars.

… Wednesday, October 1, 2025 Immunologist Chrysothemis Brown, MD, PhD , whose research has been shedding light on the development of the early life immune system and its relationship to autoimmunity, allergy, inflammation, and cancer, was among 30 early-career scientists nationwide selected for the 2025

Learn about some of the most important advances in cancer treatment at MSK in 2025.

… Monday, December 15, 2025 Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in a variety of cancer treatments in 2025 — including new approaches to immunotherapy, targeted therapy, and surgical imaging. Highlights this year also included a stem cell–based therapy for Parkinson

New research from Sloan Kettering Institute investigators pinpoints altered cell metabolism as a cause of B cell lymphoma.

… Monday, June 22, 2020 Summary Scientists at the Sloan Kettering Institute have found that increased activity of a normal metabolic enzyme can lead to cancer. The enzyme, SHMT2, is a driver of a large portion of B cell lymphomas and could be a potential drug target. Because of how aggressively they divide